Abstracts tagged "tocilizumab and tofacitinib"

Abstract Number: 2803 • 2014 ACR/ARHP Annual Meeting
Methotrexate Impacts the Effects of Tofacitinib, but Not Tocilizumab, on Clinically Relevant Biomarkers in Human Primary Cell–Based BioMAP^® Disease Models: Can We Utilize in Vitro Models to Predict Clinical Outcomes?
Alison O'Mahony¹, Ellen L. Berg¹, Xitong Li¹, Markus R. John², Kandeepan Ganeshalingam² and Ernest H. Choy³, ¹BioSeek, South San Francisco, CA, ²F. Hoffmann-La Roche, Basel, Switzerland, ³Cardiff University, Cardiff, United Kingdom
Background/Purpose: A number of trials have shown that adding MTX benefits some, but not all, biologics and small molecules to treat RA. Specifically, though treatment…
Abstract Number: 2501 • 2014 ACR/ARHP Annual Meeting
Indirect Comparison of Tocilizumab and Tofacitinib in Patients with Rheumatoid Arthritis
Stacey Chang¹, Laura Sawyer¹ and Fred Dejonckheere², ¹Symmetron Limited, London, United Kingdom, ²F. Hoffmann-La Roche, Basel, Switzerland
Background/Purpose: Tocilizumab (TCZ) is a recombinant, humanized, monoclonal antibody directed against the cytokine interleukin-6 receptor, and tofacitinib (Tofa) is an oral, synthetic, disease-modifying antirheumatic drug…
Abstract Number: 2458 • 2014 ACR/ARHP Annual Meeting
Targeting IL-6, JAK or SYK? : An Analysis of Transcriptome Alteration in Peripheral Blood By RA Treatments
Yoshinobu Koyama¹, Motohiko Tanino², Shuji Nagano³, Toshiyuki Ota³ and Toshie Higuchi¹, ¹Center for Autoimmune Diseases, Division of Rheumatology, Japan Red Cross Okayama Hospital, Okayama, Japan, ²DNA Chip Research Inc., Yokohama, Japan, ³Center for Rheumatic Diseases, Iizuka Hospital, Iizuka, Japan
Background/Purpose The advances in understanding of the molecular nature of immune cell receptors enabled to offer new oral, targeted therapies. Tofacitinib (TOF) is the first…
Abstract Number: L18 • 2014 ACR/ARHP Annual Meeting
14-3-3eta Informs Joint Pathological Mechanisms of Treatment Response to Assist with T2T Strategies
Shintaro Hirata¹, Kentaro Hanami², Anthony Marotta³ and Yoshiya Tanaka⁴, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²The first department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ³1423 Dempsey Road, Augurex Life Sciences Corp., North Vancouver, BC, Canada, ⁴University of Occupational and Environmental Health, Japan, Kitakyushu, Japan
Background/Purpose: A primary clinical goal of RA in treating to target (T2T) is to improve long term outcomes including the control of symptoms and prevention…